April 21, 2024

Ethics top priority for US biotechnology, says retiring head

The retiring head of the US biotechnology association believes that ethics is the main issue which could derail his industry. “We have paid passionate attention to bioethics issues,” Carl Feldbaum told the Seattle Times. “We have taken them dead seriously. We have gone beyond narrow commercial interests and have tried to contribute, without commandeering, debates about Dolly, stem cells and gene therapy… The mishandling of a bioethics issue could derail us in no time, but hopefully that won’t happen.”